Board/Management Information • Mar 14, 2019
Board/Management Information
Open in ViewerOpens in native device viewer
Longjumeau, March 14, 2019
The PCAS Board of Directors met on March 14, 2019, and decided to remove Mr. Vincent Touraille from his position as CEO of PCAS.
To deal with the challenges currently facing PCAS Group, the Board of Directors has selected Mr. Frédéric Desdouits as his replacement. Previously, Mr. Desdouits held the position of PCAS Deputy CEO and headed up the CDMO Business Unit.
The Board of Directors would like to warmly thank Mr. Vincent Touraille for heading PCAS since 2010 and supporting the strong development of the group.
Mr. Pierre Luzeau will continue on as Chairman of the Board of Directors.
PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in leading-edge segments. PCAS generated net sales of €206.7 million in 2018 and employs close to 1 100 people in six countries.
To find out more about PCAS, visit: www.pcas.com
| PCAS Frédéric Desdouits / Eric Moissenot |
Newcap Emmanuel Huynh / Louis-Victor Delouvrier NewCap |
|
|---|---|---|
| Tel. : +33 1 69 79 61 32 | Tel. : +33 1 44 71 98 53 | |
| www.pcas.com | [email protected] |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.